GlassScriptPhysician profile
Nelson Garcia
NPI 1598734055
$15,784.77
in general payments reported to CMS, 2019-2025
45 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,086 · 2020: $715 · 2021: $2,103 · 2022: $2,201 · 2023: $2,796 · 2024: $2,682 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,586 · Education: $93.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,586.21 |
| Education | $93.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,538.74 | 2019-2025 | |
| Janssen Biotech, INC. | $2,298.25 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $1,453.09 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,210.06 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $825.35 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $646.43 | 2019-2025 | Airsupra, Breztri |
| Celgene Corporation | $544.32 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $538.84 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $483.50 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $458.03 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $379.68 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $360.44 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $351.56 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $343.67 | 2024-2025 | Iqirvo |
| Pfizer INC. | $323.34 | 2023-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $305.64 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $275.98 | 2021-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $254.59 | 2021-2023 | |
| Daiichi Sankyo INC. | $218.78 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $214.19 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $212.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $152.48 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $145.34 | 2024-2025 | Vegzelma |
| Novo Nordisk INC | $142.75 | 2025 | Ozempic, Wegovy |
| Redhill Biopharma INC. | $139.97 | 2021-2025 | Talicia |
| Merck Sharp & Dohme LLC | $139.59 | 2021-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.45 | 2019-2023 | Cyltezo |
| Exact Sciences Corporation | $108.05 | 2023-2024 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $106.21 | 2023-2025 | Rebyota, Clenpiq |
| Braintree Laboratories, INC. | $86.99 | 2021-2024 | Sutab, Suflave |
| Alnylam Pharmaceuticals INC. | $70.65 | 2022-2024 | Givlaari |
| Evoke Pharma, INC. | $50.80 | 2023-2025 | Gimoti |
| Amgen INC. | $39.73 | 2023 | Avsola, Amjevita |
| Allergan, INC. | $38.65 | 2019-2020 | |
| Vivus LLC | $31.16 | 2021-2023 | Qsymia |
| Fujifilm Healthcare Americas Corporation | $22.35 | 2024 | Fujifilm |
| Alfasigma USA, INC. | $19.07 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.22 | 2023 | Monoferric |
| Shire North American Group INC | $16.58 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.12 | 2021 | |
| Boston Scientific Corporation | $15.80 | 2019 | |
| Olympus America INC. | $14.91 | 2024 | Single Use Electrosurgical Knife Kd-655 |
| Romark Laboratories, Lc | $14.45 | 2020 | |
| Pentax of America, INC. | $11.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.